In silico binding free energy predictability by using the linear interaction energy (LIE) method: Bromobenzimidazole CK2 inhibitors as a case study

被引:25
作者
Bortolato, A. [1 ]
Moro, S. [1 ]
机构
[1] Univ Padua, Dept Pharmaceut Sci, Mol Modeling Sect, I-35131 Padua, Italy
关键词
D O I
10.1021/ci600369n
中图分类号
R914 [药物化学];
学科分类号
100701 ;
摘要
Protein kinase CK2 is essential for cell viability, and its control regards a broad series of cellular events such as gene expression, RNA, and protein synthesis. Evidence of its involvement in tumor development and viral replication indicates CK2 as a potential target of antineoplastic and antiviral drugs. In this study the Linear Interaction Energy (LIE) Method with the Surface Generalized Born (SGB) continuum solvation model was used to study several bromobenzimidazole CK2 inhibitors. This methodology, developed by Aqvist, finds a plausible compromise between accuracy and computational speed in evaluating binding free energy (Delta G(bind)) values. In this study, two different free binding energy models, named "CK2scoreA" and "CK2scoreB", were developed using 22 inhibitors as the training set in a stepwise approach useful to appropriately select both the tautomeric form and the starting binding position of each inhibitor. Both models are statistically acceptable. Indeed, the better one is characterized by a correlation coefficient (r(2)) of 0.81, and the predictive accuracy was 0.65 kcal/mol. The corresponding validation, using an external test set of 16 analogs, showed a correlation coefficient (q(2)) of 0.68 and a prediction root-mean-square error of 0.78 kcal/mol. In this case, the LIE approach has been proved to be an efficient methodology to rationalize the difference of activity, the key interactions, and the different possible binding modes of this specific class of potent CK2 inhibitors.
引用
收藏
页码:572 / 582
页数:11
相关论文
共 61 条
[1]   Relationship between flavonoid structure and inhibition of phosphatidylinositol 3-kinase: A comparison with tyrosine kinase and protein kinase C inhibition [J].
Agullo, G ;
GametPayrastre, L ;
Manenti, S ;
Viala, C ;
Remesy, C ;
Chap, H ;
Payrastre, B .
BIOCHEMICAL PHARMACOLOGY, 1997, 53 (11) :1649-1657
[2]   Polyhalogenobenzimidazoles: Synthesis and their inhibitory activity against casein kinases [J].
Andrzejewska, M ;
Pagano, MA ;
Meggio, F ;
Brunati, AM ;
Kazimierczuk, Z .
BIOORGANIC & MEDICINAL CHEMISTRY, 2003, 11 (18) :3997-4002
[3]   NEW METHOD FOR PREDICTING BINDING-AFFINITY IN COMPUTER-AIDED DRUG DESIGN [J].
AQVIST, J ;
MEDINA, C ;
SAMUELSSON, JE .
PROTEIN ENGINEERING, 1994, 7 (03) :385-391
[4]   The replacement of ATP by the competitive inhibitor emodin induces conformational modifications in the catalytic site of protein kinase CK2 [J].
Battistutta, R ;
Sarno, S ;
De Moliner, E ;
Papinutto, E ;
Zanotti, G ;
Pinna, LA .
JOURNAL OF BIOLOGICAL CHEMISTRY, 2000, 275 (38) :29618-29622
[5]   Inspecting the structure-activity relationship of protein kinase CK2 inhibitors derived from tetrabromo-benzimidazole [J].
Battistutta, R ;
Mazzorana, M ;
Sarno, S ;
Kazimierczuk, Z ;
Zanotti, G ;
Pinna, LA .
CHEMISTRY & BIOLOGY, 2005, 12 (11) :1211-1219
[6]   Structural features underlying selective inhibition of protein kinase CK2 by ATP site-directed tetrabromo-2-benzotriazole [J].
Battistutta, R ;
De Moliner, E ;
Sarno, S ;
Zanotti, G ;
Pinna, LA .
PROTEIN SCIENCE, 2001, 10 (11) :2200-2206
[7]   The Protein Data Bank [J].
Berman, HM ;
Westbrook, J ;
Feng, Z ;
Gilliland, G ;
Bhat, TN ;
Weissig, H ;
Shindyalov, IN ;
Bourne, PE .
NUCLEIC ACIDS RESEARCH, 2000, 28 (01) :235-242
[8]   Oncogenic kinase signalling [J].
Blume-Jensen, P ;
Hunter, T .
NATURE, 2001, 411 (6835) :355-365
[9]   Computational analysis of binding of P1 variants to trypsin [J].
Brandsdal, BO ;
Åqvist, J ;
Smalås, AO .
PROTEIN SCIENCE, 2001, 10 (08) :1584-1595
[10]   The shape of things to come: An emerging role for protein kinase CK2 in the regulation of cell morphology and the cytoskeleton [J].
Canton, DA ;
Litchfield, DW .
CELLULAR SIGNALLING, 2006, 18 (03) :267-275